ReviewCanadian family physician Medecin de famille canadien2011
Buprenorphine: new treatment of opioid addiction in primary care.
Review in Canadian family physician Medecin de famille canadien, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.Addiction science & clinical practice · 2019Pooled it
- Primary care models for treating opioid use disorders: What actually works? A systematic review.PloS one · 2017Pooled it
- Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations.Canadian family physician Medecin de famille canadien · 2011Guideline
- Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood.Oxidative medicine and cellular longevity · 2019Trial
- Overview of best practices for buprenorphine initiation in the emergency department.International journal of emergency medicine · 2024Article
- How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis.BMJ open · 2022Article
- A Facility-Wide Plan to Increase Access to Medication for Opioid Use Disorder in Primary Care and General Mental Health Settings.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021Article
- The Abuse Characteristics of Amphetamine-Type Stimulants in Patients Receiving Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment.Drug design, development and therapy · 2021Article
- Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.Substance abuse treatment, prevention, and policy · 2017Article
- Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.The journal of behavioral health services & research · 2017Article
- Treatment of prescription opioid disorders in Canada: looking at the 'other epidemic'?Substance abuse treatment, prevention, and policy · 2016Article
- Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.Addictive behaviors · 2014Article
- Perioperative Pain Management for Patients on Chronic Buprenorphine: A Case Report.Journal of anesthesia & clinical research · 2013Article
- Can you vaccinate against substance abuse?Expert opinion on biological therapy · 2013Review
- A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats.Progress in neuro-psychopharmacology & biological psychiatry · 2013Article
- Article
- Nicotine vaccines to treat tobacco dependence.Human vaccines & immunotherapeutics · 2013Review
- Agonist-selective effects of opioid receptor ligands on cytosolic calcium concentration in rat striatal neurons.Drug and alcohol dependence · 2012Article
- Update on the clinical use of buprenorphine: in opioid-related disorders.Canadian family physician Medecin de famille canadien · 2012Review
- Vaccines against drug abuse.Clinical pharmacology and therapeutics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo review the use of buprenorphine for opioid-addicted patients in primary care. QUALITY OF EVIDENCE: The MEDLINE database was searched for literature on buprenorphine from 1980 to 2009. Controlled trials, meta-analyses, and large observational studies were reviewed. MAIN MESSAGE: Buprenorphine is a partial opioid agonist that relieves opioid withdrawal symptoms and cravings for 24 hours or longer. Buprenorphine has a much lower risk of overdose than methadone and is preferred for patients at high risk of methadone toxicity, those who might need shorter-term maintenance therapy, and those with limited access to methadone treatment. The initial dose should be given only after the patient is in withdrawal. The therapeutic dose range for most patients is 8 to 16 mg daily. It should be dispensed daily by the pharmacist with gradual introduction of take-home doses. Take-home doses should be introduced more slowly for patients at higher risk of abuse and diversion (eg, injection drug users). Patients who fail buprenorphine treatment should be referred for methadone- or abstinence-based treatment.
conclusionBuprenorphine is an effective treatment of opioid addiction and can be safely prescribed by primary care physicians.
Indexed as
Identifiers
21402963PMC3056674W2147057496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.